ArticleScientific reports2025
A cross-sectional study on fear of progression in patients with myasthenia gravis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Myasthenia Gravis With Acetylcholine Receptor Antibodies in the Very Old: Treatment Challenges and Diagnostic Pitfalls.European journal of neurology · 2026Pooled it
- Current status and challenges of biologic targeted therapy for myasthenia gravis in China.Intractable & rare diseases research · 2026Review
- Prevalence and associated factors of fear of progression in patients with heart failure in China: a scoping review.Frontiers in psychiatry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Patients with myasthenia gravis (MG) are prone to resulting in a significant psychological burden. This study aims to investigate the condition of fear of progression (FoP) and identify factors associated with FoP among MG patients. This cross-sectional study included 83 patients with MG admitted to the First Affiliated Hospital of Nanchang University from January to November 2024. Data were collected through clinical records and questionnaires, including demographic details, disease duration, comorbidities, current drug regimen, and the fear of progression questionnaire-short form (FoP-Q-SF). The simplified fear of progression scale score for 83 MG patients was 31.36 ± 10.22. Among these participants, 38.6% exhibited dysfunction FoP. There was no significant difference concerning age, marital status, course of the disease, crisis of MG, STAI score, and TAI score in the total score of fear of disease progression in MG patients. However, gender, progress of MG and MGFA classification were positively correlated with the fear of progression (P < 0.05), which was statistically significant. Furthermore, gender and disease progression were identified as factors influencing FoP in MG patients (P < 0.05). FoP among MG patients varies according to their socio-demographic and clinical characteristics. Gender and progress history of MG are associated with Fop.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.